A novel mutant of human papillomavirus type 18 E6E7 fusion gene and its transforming activity

Asian Pacific Journal of Cancer Prevention

Volumn 15, Issue 17, 2014, Pages 7395-7399

  Zhou, Zhi Xiang ^a   Zhao, Chen ^a   Li, Qian Qian ^a   Zeng, Yi ^a  

^a BEIJING UNIVERSITY OF TECHNOLOGY   (China)

Author keywords

Cervical cancer; E6 E7; Human papillomavirus 18; Therapeutic vaccine

Indexed keywords

DNA BINDING PROTEIN; E6 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 18; E7 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 18; ONCOPROTEIN;

3T3 CELL LINE; ANIMAL; BAGG ALBINO MOUSE; GENE FUSION; GENETICS; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 18; MOUSE; NUDE MOUSE; PHYSIOLOGY; SITE DIRECTED MUTAGENESIS; VIRUS CELL TRANSFORMATION;

ANIMALS; ARTIFICIAL GENE FUSION; CELL TRANSFORMATION, VIRAL; DNA-BINDING PROTEINS; HUMAN PAPILLOMAVIRUS 18; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; MUTAGENESIS, SITE-DIRECTED; NIH 3T3 CELLS; ONCOGENE PROTEINS, VIRAL;

EID: 84907267811     PISSN: 15137368     EISSN: None     Source Type: Journal    
DOI: 10.7314/APJCP.2014.15.17.7395     Document Type: Article

References (14)

1. Balsitis S, Dick F, Dyson N, et al (2006). Critical roles for non-pRb targets of human papillomavirus type 16 E7 in cervical carcinogenesis. Cancer Res, 66, 9393-400.
2. Cannon G, Gupta P, Gomes F, et al (2012). Prevention of cancer and non-communicable diseases. Asian Pac J Cancer Prev, 13, 3-9.
3. Farhath S, Vijaya P, Mumtaj P (2013). Cervical cancer: Is vaccination necessary in India? Asian Pac J Cancer Prev, 14, 2681-4.
4. Govan VA (2005). Strategies for human papillomavirus therapeutic vaccines and other therapies based on the E6 and E7 oncogenes. Ann N Y Acad Sci, 1056, 328-43.
5. Ham S, Kim KH, Kwon TH, et al (2014). Luteolin induces intrinsic apoptosis via inhibition of E6/E7 oncogenes and activation of extrinsic and intrinsic signaling pathways in HPV-18-associated cells. Oncol Rep, 31, 2683-91.
6. Li Q, Zhou ZX, Sheng W, Zeng Y (2013). HPV18 carcinogenic mechanisms and vaccine research. Modern Prev Med, 49, 1140-2.
7. Mcintyre MC, Frattini MG, Grossman SR et al (1993). Human papillomavirus type 18 E7 protein requires intact Cys-X-X-Cys motifs for zinc binding, dimerization, and transformation but not for Rb binding. J Virol , 67, 3142-50.
8. Narisawa-Saito M, Kiyono T (2007). Basic mechanisms of high-risk human papillomavirus-induced carcinogenesis: roles of E6 and E7 proteins. Cancer Sci, 98, 1505-11.
9. Nelson EA, Lam HS, Choi KC, et al (2013). Ho WC, Fung LW, Cheng FW, Sung RY, Royals M, Chan PK. A pilot randomized study to assess immunogenicity, reactogenicity, safety and tolerability of two human papillomavirus vaccines administered intramuscularly and intradermally to females aged 18-26 years. Vaccine, 31, 3452-60.
10. Ohlschlager P, Quetting M, Alvarez G, et al (2009). Enhancement of immunogenicity of a therapeutic cervical cancer DNA-based vaccine by co-application of sequenceoptimized genetic adjuvants. Int J Cancer, 125, 189-98.
11. Pang CL, Thierry F (2013). Human papillomavirus proteins as prospective therapeutic targets. Microb Pathog, 58, 55-65.
12. Powell N, Cuschieri K, Cubie H, et al (2013). Cervical cancers associated with human papillomavirus types 16, 18 and 45 are diagnosed in younger women than cancers associated with other types: a cross-sectional observational study in Wales and Scotland (UK). J Clin Virol, 58, 571-4.
13. Siriaunkgul S, Utaipat U, Suwiwat S, et al (2012). Prognostic value of HPV18 DNA viral load in patients with early-stage neuroendocrine carcinoma of the uterine cervix. Asian Pac J Cancer Prev, 13, 3281-5.
14. Xie Q, Zhou ZX, Li Z, et al (2011). Transforming activity of a novel mutant of HPV16 E6E7 fusion gene. Virologica Sinica, 26, 206-13.